Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 361

1.

Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus.

Cho E, Ryu EJ, Jiang F, Jeon UB, Cho M, Kim CH, Kim M, Kim ND, Hwang TH.

Drug Des Devel Ther. 2018 Aug 8;12:2467-2474. doi: 10.2147/DDDT.S171269. eCollection 2018.

2.

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.

Kowalsky SJ, Liu Z, Feist M, Berkey SE, Ma C, Ravindranathan R, Dai E, Roy EJ, Guo ZS, Bartlett DL.

Mol Ther. 2018 Jul 17. pii: S1525-0016(18)30338-1. doi: 10.1016/j.ymthe.2018.07.013. [Epub ahead of print]

3.

Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.

Ylösmäki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, Ylösmäki L, Louna A, Feola S, Paavilainen H, Peltonen K, Hukkanen V, Viitala T, Cerullo V.

Mol Ther. 2018 Jun 19. pii: S1525-0016(18)30267-3. doi: 10.1016/j.ymthe.2018.06.008. [Epub ahead of print]

4.

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.

Ricordel M, Foloppe J, Antoine D, Findeli A, Kempf J, Cordier P, Gerbaud A, Grellier B, Lusky M, Quemeneur E, Erbs P.

Cancers (Basel). 2018 Jul 10;10(7). pii: E231. doi: 10.3390/cancers10070231.

5.

Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer.

Choi AH, O'Leary MP, Lu J, Kim SI, Fong Y, Chen NG.

Mol Ther Oncolytics. 2018 Apr 5;9:22-29. doi: 10.1016/j.omto.2018.04.001. eCollection 2018 Jun 29.

6.

Oncolytic Viruses for Multiple Myeloma Therapy.

Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST.

Cancers (Basel). 2018 Jun 14;10(6). pii: E198. doi: 10.3390/cancers10060198. Review.

7.

Exploring the role of oncolytic viruses in hepatobiliary cancers.

Tenneti P, Borad MJ, Babiker HM.

Immunotherapy. 2018 Jun 14. doi: 10.2217/imt-2018-0048. [Epub ahead of print]

PMID:
29900755
8.

Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus.

Burgess HM, Pourchet A, Hajdu CH, Chiriboga L, Frey AB, Mohr I.

Mol Ther Oncolytics. 2018 Jan 31;8:71-81. doi: 10.1016/j.omto.2018.01.001. eCollection 2018 Mar 30.

9.

Tachypleus tridentatus Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth.

Li G, Cheng J, Mei S, Wu T, Ye T.

Mar Drugs. 2018 Jun 7;16(6). pii: E200. doi: 10.3390/md16060200.

10.

Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.

Lauer UM, Schell M, Beil J, Berchtold S, Koppenhöfer U, Glatzle J, Königsrainer A, Möhle R, Nann D, Fend F, Pfannenberg C, Bitzer M, Malek NP.

Clin Cancer Res. 2018 May 17. doi: 10.1158/1078-0432.CCR-18-0244. [Epub ahead of print]

PMID:
29773661
11.

The emerging role of oncolytic virus therapy against cancer.

Russell L, Peng KW.

Chin Clin Oncol. 2018 Apr;7(2):16. doi: 10.21037/cco.2018.04.04.

12.

Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.

Marelli G, Howells A, Lemoine NR, Wang Y.

Front Immunol. 2018 Apr 26;9:866. doi: 10.3389/fimmu.2018.00866. eCollection 2018. Review.

13.

Haliotis discus discus Sialic Acid-Binding Lectin Reduces the Oncolytic Vaccinia Virus Induced Toxicity in a Glioblastoma Mouse Model.

Li G, Mei S, Cheng J, Wu T, Luo J.

Mar Drugs. 2018 Apr 26;16(5). pii: E141. doi: 10.3390/md16050141.

14.

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy.

Allan KJ, Mahoney DJ, Baird SD, Lefebvre CA, Stojdl DF.

J Vis Exp. 2018 Apr 3;(134). doi: 10.3791/56913.

PMID:
29683442
15.

Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.

White M, Freistaedter A, Jones GJB, Zervos E, Roper RL.

PLoS One. 2018 Feb 23;13(2):e0193131. doi: 10.1371/journal.pone.0193131. eCollection 2018.

16.

New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.

Lundstrom K.

Biologics. 2018 Feb 9;12:43-60. doi: 10.2147/BTT.S140114. eCollection 2018. Review.

17.

Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, Gannage M, Dréno B, Vaivode K, Pjanova D, Labarrière N, Wang Y, Chiocca EA, Boeuf FL, Bell JC, Erbs P, Tangy F, Grégoire M, Fonteneau JF.

Oncoimmunology. 2017 Dec 26;7(3):e1407897. doi: 10.1080/2162402X.2017.1407897. eCollection 2018.

PMID:
29399408
18.

Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.

Moon EK, Wang LS, Bekdache K, Lynn RC, Lo A, Thorne SH, Albelda SM.

Oncoimmunology. 2018 Jan 9;7(3):e1395997. doi: 10.1080/2162402X.2017.1395997. eCollection 2018.

PMID:
29399394
19.

Labeling and Single-Particle-Tracking-Based Entry Mechanism Study of Vaccinia Virus from the Tiantan Strain.

Huang LL, Wu LL, Li X, Liu K, Zhao D, Xie HY.

Anal Chem. 2018 Mar 6;90(5):3452-3459. doi: 10.1021/acs.analchem.7b05183. Epub 2018 Feb 14.

PMID:
29392930
20.

Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways.

Mejías-Pérez E, Carreño-Fuentes L, Esteban M.

Mol Ther Oncolytics. 2017 Dec 5;8:27-40. doi: 10.1016/j.omto.2017.12.002. eCollection 2018 Mar 30.

Supplemental Content

Loading ...
Support Center